


II. CLAIM AMENDMENTS

1. (Currently Amended) ~~substituted benzo[b]azepin-2-one~~
~~compounds of the general A compound of formulae I or and II and~~
~~in each case the tautomers thereof,~~



in which

R' , R^2 , R^3 and R^4 , identical or different, denote a
 linear or branched, saturated or unsaturated aliphatic
 C_{1-10} ~~residue~~ or a saturated or unsaturated
 cycloaliphatic C_{3-7} group residue, wherein each of the above-
 stated groups residues may optionally be bonded ~~joined together~~
 via
 an ether bridge, or hydrogen, a halogen or a hydroxy
 group,

R^5 denotes hydrogen, a linear or branched, saturated
 or unsaturated aliphatic C_{1-10} group residue, or an aryl group ~~or a~~
~~heteroaryl residue~~,

R^6 denotes hydrogen or a group residue of the formula $-CH_2-NR^7_2$,
 wherein the two groups R^7 ~~residues~~ are identical or different











and have the meaning stated below or may form a 3-8-membered ring together with the nitrogen atom connecting them as a ring member,


R⁷ denotes a linear or branched, saturated or unsaturated aliphatic C₁₋₆ group residue or a saturated or unsaturated cycloaliphatic C₃₋₆ group residue,

A denotes a bridge with one of the following formulae:

- (CH₂)_{n+2}⁻, - (CH₂)_n-CH=CH-, - (CH₂)_nCOO-, - (CH₂)_nCONH-, -
(CH₂)_{n+1}⁰(CH₂)_pCO-, - (CH₂)_{n+1}⁰-, - (CH₂)_{n+1} NR^{1'}- in which n denotes
0, 1, 2, or 3, and p denotes 0 or 1, R'' has the meaning stated
hereinafter and the bond to the residue group X is always stated
last and ~~wherein bonding of the residues X¹⁷ and X¹⁸ is possible
only via the three bridges stated first,~~

and X denotes one of the following groups residues of the
general formulae X¹ to X⁶ and X¹⁶ ~~X¹⁸~~, in which the unoccupied bond
line symbolises the bond to the bridge A and





in which

R^{1'} denotes hydrogen, a linear or branched, saturated or unsaturated aliphatic C₁₋₁₀ group residue, a saturated or unsaturated cycloaliphatic C₃₋₇ group residue, or an aryl or heteroaryl group residue,

R^{2'} denotes a linear or branched, saturated or unsaturated aliphatic C₁₋₁₀ group residue, a saturated or unsaturated

cycloaliphatic C₃₋₇ ~~residue group~~ or an aryl group or

~~heteroaryl residue~~ wherein all above-stated groups ~~residues~~ may optionally be joined via an ether, thioether or SO² bridge, or hydrogen, a halogen, a hydroxy, thiol, cyano or nitro group or a group of the formula -NR^{1'2} wherein the two groups ~~residues~~ R^{1'} are identical or different and have the above-stated meaning,

R^{3'} denotes a linear or branched, saturated or unsaturated aliphatic C₁₋₁₀ group ~~residue~~, a saturated or unsaturated cycloaliphatic C₃₋₇ group ~~residue~~, an aryl or ~~heteroaryl~~ group ~~residue~~, wherein all the above-stated group ~~residues~~ may optionally be joined via an ether or an ester bridge, hydrogen, a halogen, a hydroxy group,

R^{4'} denotes hydrogen, an aryl or ~~heteroaryl~~ group ~~residue~~, wherein the aryl or ~~heteroaryl~~ residue group may comprise at least one substituent R^{2'} with the above meaning, with the exception of hydrogen,

R^{5'} denotes a ~~residue~~ of the formula -NR^{6'2}, wherein the two ~~residues~~ R^{6'} may be identical or different and have the meaning stated hereinafter or may form a 3-7-membered ring together with the nitrogen atom connecting them as a ring member, which ring may optionally contain at least one oxygen and/or at least one further nitrogen as a ring atom, wherein the nitrogen may comprise a substituent R^{10'} with the meaning stated hereinafter,

R^{6'} denotes a linear or branched, saturated or unsaturated aliphatic C₁₋₆ group ~~residue~~, a saturated or unsaturated or

cycloaliphatic C₃₋₇ group residue, an aryl ~~or heteroaryl~~ group residue,

~~R^{7'} denotes a cyano, amide or carboxylic acid residue,~~

~~R^{8'} denotes a residue of the formula NR^{9'}₂, wherein the two residues R^{9'} may be identical or different and have the meaning stated hereinafter or may form a 3-7 membered ring together with the nitrogen atom connecting them as a ring member, which ring may optionally contain at least one oxygen and/or at least one further nitrogen as a ring atom,~~

R^{9'} denotes hydrogen, a linear or branched aliphatic C₁₋₁₀ residue,

R^{10'} denotes hydrogen, a linear or branched, saturated or unsaturated aliphatic C₁₋₁₀ group residue, an aryl ~~or heteroaryl~~ group residue and

Z denotes at least one optionally present ~~oxygen, sulfur or~~ nitrogen as a ring atom,

and q denotes 0, 1, 2 or 3,

optionally in the form of the racemates thereof, the pure stereoisomers thereof, ~~in particular enantiomers or diastereomers,~~ or in the form of mixtures of the stereoisomers, ~~in particular the enantiomers or diastereomers,~~ in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof, ~~in particular~~

~~physiologically acceptable salts,~~ or in the form of the solvates thereof, ~~in particular hydrates.~~

2. (Currently Amended) ~~Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof~~ A compound according to claim 1, characterised in that R^2 and R^3 , identical or different, denote a linear or branched, saturated or unsaturated aliphatic C^{1-3} ~~residue~~ or a halogen and R^1 and R_4 in each case denote hydrogen, R^5 denotes hydrogen or a linear or branched, saturated or unsaturated aliphatic C_{1-3} group ~~residue~~ and R^6 denotes hydrogen or a group ~~residue~~ of the formula $-CH_2-NR^7_2$, in which R^7 denotes a linear or branched, saturated or unsaturated aliphatic C_{1-3} group ~~residue~~, optionally in the form of the racemates thereof, the pure stereoisomers thereof, in particular enantiomers or diastereomers, or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof, in particular physiologically acceptable salts, or in the form of the solvates thereof, in particular hydrates.

3. (Currently Amended) Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof A compound according to claim 1, characterised in that R_2 and R_3 in each case denote a methyl group or a chlorine and R_1 and R_4 in each case denote hydrogen, R_5 denotes hydrogen or a methyl group and R_6 denotes hydrogen or a group residue of the formula $-CH_2-N(CH_3)_2$, optionally in the form of the racemates thereof, the pure stereoisomers thereof, ~~in particular enantiomers or diastereomers,~~ or in the form of mixtures of the stereoisomers,

~~in particular enantiomers or diastereomers,~~ in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof,~~in particular physiologically acceptable salts,~~ or in the form of the solvates thereof,~~in particular hydrates.~~

4. (Currently Amended) ~~Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof~~ A compound according to claim 1, characterized in that R^3 denotes a linear or branched, saturated or unsaturated aliphatic C_{1-3} ~~residue~~ or a halogen and R^1 , R^2 and R^4 in each case denote hydrogen, R^5 denotes hydrogen or a linear or branched, saturated or unsaturated aliphatic C_{1-3} group residue and R^6 denotes hydrogen or a group residue of the formula $-CH_2-N(R^7)_2$, in which R^7 denotes a linear or branched, saturated or unsaturated aliphatic C_{1-3} group residue, optionally in the form of the racemates thereof, the pure stereoisomers thereof,~~in particular enantiomers or diastereomers,~~ or in the form of mixtures of the stereoisomers,~~in particular the enantiomers or diastereomers,~~ in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof,~~in particular physiologically acceptable salts,~~ or in the form of the solvates thereof,~~in particular hydrates.~~

5. (Currently Amended) ~~Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof~~ A compound according to claim 1, characterised in that R^3 denotes a methyl group or a chlorine and R^1 , R^2 and R^4 in each case denote hydrogen, R^5 denotes hydrogen or a methyl group and R^6 denotes hydrogen or a ~~residue~~ of the formula $-CH_2-N(CH_3)_2$, optionally in

the form of the racemates thereof, the pure stereoisomers thereof, ~~in particular enantiomers or diastereomers~~, or in the form of mixtures of the stereoisomers, ~~in particular enantiomers or diastereomers~~, in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof, ~~in particular physiologically acceptable salts~~, or in the form of the solvates thereof, ~~in particular hydrates~~.


6. (Currently Amended) Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof A compound according to claim 1, characterised in that R^1 and R^3 , identical or different, denote a linear or branched, saturated or unsaturated aliphatic c_{1-3} group residue or a halogen and R^2 and R^4 in each case denote hydrogen, R^5 denotes hydrogen or a linear or branched, saturated or unsaturated aliphatic c_{1-3} group residue and R^6 denotes hydrogen or a group residue of the formula $-CH_2-NR^7_2$, in which R^7 denotes a linear or branched, saturated or is unsaturated aliphatic c_{1-3} group residue, optionally in the form of the racemates thereof, the pure stereoisomers thereof, ~~in particular enantiomers or diastereomers~~, or in the form of mixtures of the stereoisomers, ~~in particular the enantiomers or diastereomers~~, in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof, ~~in particular physiologically acceptable salts~~, or in the form of the solvates thereof, ~~in particular hydrates~~.

7. (Currently Amended) ~~Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof~~ A compound according to claim 1, characterised in that R^1 and R^3 in each case denote a methyl group or a chlorine and R^2 and R^4 in each case

denote hydrogen, R^5 denotes hydrogen or a methyl group and R^6 denotes hydrogen or a residue of the formula $-CH_2-N(CH_3)_2$, optionally in the form of the racemates thereof, the pure stereoisomers thereof, ~~in particular enantiomers or diastereomers~~, or in the form of mixtures of the stereoisomers, ~~in particular enantiomers or diastereomers~~, in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof, ~~in particular physiologically acceptable salts~~, or in the form of the solvates thereof, ~~in particular hydrates~~.

8. (Currently Amended) ~~Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof~~ A compound according to one of claims 1-7, characterised in that A denotes a bridge of the formula $-CH_2-COO-$ or $-CH_2CONH-$ optionally in form of the racemates thereof, the pure stereoisomers thereof, in particular enantiomers or diastereomers, or in the form of mixtures of the stereoisomers, ~~in particular the enantiomers or diastereomers~~, in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof, ~~in particular physiologically acceptable salts~~, or in the form of the solvates thereof, ~~in particular hydrates~~.

9. (Currently Amended) ~~Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof~~ A compound according to one of claims 1-8, characterised in that X denotes a group residue of the following formula:



optionally in the form of the racemates thereof, the pure stereoisomers thereof, ~~in particular enantiomers or diastereomers,~~ or in the form of mixtures of the stereoisomers, ~~in particular the enantiomers or diastereomers,~~ in any desired mixing ratio or in each case in the form of the acids or bases thereof or in the form of the salts thereof, ~~in particular physiologically acceptable salts,~~ or in the form of the solvates thereof, ~~in particular hydrates.~~

10. (Currently Amended) ~~Substituted benzo[b]azepin-2-one compounds and in each case the tautomers thereof~~ A compound according to claim 1 which is:

2'-(8-Chloro-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl)acetic acid [3''-(N,N-dimethylaminomethyl)-4''-hydroxy-4''-(m-methoxyphenyl)cyclohexyl] ester,

2'-(8-Chloro-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl)
acetic acid [3"-(N,N-dimethylaminomethyl)-4"-hydroxy-4"-(m-
methoxyphenyl)cyclohexyl] ester,


2'-(8-Chloro-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl)-N-[3"-
N,N-dimethylaminomethyl)-4"-hydroxy-4"-(m-
methoxyphenyl)cyclohexyl]acetamide,

2'-(8-Chloro-1-methyl-2-oxo-2,3-dihydro-1H-benzo[b]azepin-5-yl)-
N-[3"-(N,N-dimethylaminomethyl)-4"-hydroxy-4"-(m-
methoxyphenyl)cyclohexyl]acetamide,


optionally in the form of the racemates thereof, the pure
stereoisomers thereof, ~~in particular enantiomers or~~
~~diastereomers~~, or in the form of mixtures of the stereoisomers,
~~in particular the enantiomers or diastereomers~~, in any desired
mixing ratio or in each case in the form of the acids or bases
thereof or in the form of the salts thereof, ~~in particular~~
~~physiologically acceptable salts~~, or in the form of the solvates
thereof, ~~in particular hydrates~~.

11. (Currently Amended) A process for the production of
~~substituted benzo[b]azepin-2-one compounds, the tautomers and~~
~~corresponding stereoisomers thereof~~ a compound according to one
of claims 1-10, characterised in that


A) an optionally substituted 2-aminobenzoic alkyl ester
of the ~~general~~ formula (1), in which R¹, ~~25~~ R², R³, R⁴ and R⁵
have the same meaning as in claim 1 ~~one of claims 1-7~~ and R
denotes an alkyl group, ~~preferably a methyl or ethyl group,~~




is reacted with succinic acid dialkyl ester of the ~~general~~ formula (2), in which R' denotes an alkyl group, ~~preferably a methyl or ethyl group~~ and R^x denotes chlorine or an alkoxy group, ~~preferably a methoxy or ethoxy group,~~




under suitable reaction conditions, in a suitable solvent, ~~preferably pyridine,~~ and is then worked up, optionally followed by purification of the optionally substituted N- (2-carbalkoxyphenyl)succinic acid alkyl ester amide formed of the ~~general~~ formula (3), in which R, R', R¹, R², R³, R⁴ and R⁵ have the above-stated meaning




B) an optionally substituted N-(2-carboalkoxyphenyl)succinic acid alkyl ester amide of the ~~general~~ formula (3) is reacted in the presence of potassium tert-butanolate in a suitable solvent and then worked up, optionally followed by purification of the optionally substituted 5-hydroxy-2-oxo-2,3-dihydro-1H-benzo[b]azepin-4-carboxylic acid alkyl ester formed of the general formula (4), in which R', R¹, R², R³, R⁴ and R⁵ have the above-stated meaning,




C) an optionally substituted 5-hydroxy-2-oxo-2,3-dihydro-1H-benzo[b]azepin-4-carboxylic acid alkyl ester of the general formula (4) is reacted in a dimethyl sulfoxide/Water mixture at elevated temperature and then worked up, optionally followed by purification of the optionally substituted 2,3,4, 5-tetrahydro-1H-benzo[b]azepin-2,5-dione of the general formula (5), in which R', R², R³ R⁴ and ⁵ have the above-stated meaning,




D) an optionally substituted 2,3,4,5-tetrahydro-1H-benzo[b]azepin-2,5-dione of the ~~general~~ formula (5) is reacted with a substituted aminomethyl hydrochloride of the ~~general~~ formula (6), in which the group residue ~~residue~~ R^7 has the meaning stated in claim 1,




in the presence of an acid, ~~preferably acetyl chloride~~, in a suitable solvent, ~~preferably acetonitrile~~, and then worked up, optionally followed by purification of the optionally substituted aminomethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-2,5-dione of the ~~general~~ formula (7), in which R^1 , R^2 , R^3 , R^4 , R^5 and R^7 have the above-stated meaning,



E) an optionally substituted 2,3,4,5-tetrahydro-1H-benzo[b]azepin-2,5-dione of the ~~general~~ formula (8), in which R^1 , R^2 , R^3 , R^4 , R^5 and R^6 have the same meaning as in ~~one of claims 1-7~~ claim 1 and which combines the compounds of the ~~general~~ formulae (5) and (7)




is reacted with a phosphonoalkanoic acid trialkyl ester of the ~~general~~ formula (9), in which n has the same meaning as in claim 1 and R'' denotes an alkyl group, ~~preferably a methyl or ethyl group,~~



in the presence of a base, ~~preferably potassium tert-butanolate,~~ in a suitable solvent, ~~preferably dimethylformamide~~ and then worked up, optionally followed by Purification of the compound formed of the formula $Y-COOR''$ in which R'' has the above stated meaning and Y denotes a group residue of the ~~general~~ formula Y , in which the unoccupied bond line symbolises the bond

to the group residue -COOR" and



in which R', R², R³, R⁴, R⁵, R⁶ and n have the above-stated meaning.

F) optionally an ester of the formula Y-COOR" is reacted in the presence of a base, ~~preferably sodium or potassium hydroxide,~~ in a suitable solvent, ~~preferably an alcohol/water mixture,~~ and then worked up, optionally followed by Purification of the carboxylic acid formed of the formula Y-COOH in which Y has the above-stated meaning,

G) optionally a carboxylic acid of the formula Y-COOH or a carboxylic acid ester of the formula Y-COOR" in which Y and R" have the above stated meaning, is derivatised in that

a) a carboxylic acid or carboxylic acid ester of the formula Y-COOH or Y-COOR" is reduced with the assistance of reducing agents, preferably lithium aluminium hydride, in a

suitable solvent, preferably tetrahydrofuran, to the corresponding alcohol of the formula $Y-CH_2-OH$,


b) a carboxylic acid or carboxylic acid ester of the formula $Y-COOH$ or $Y-COOR''$ is reduced with the assistance of reducing agents, ~~preferably diisobutylaluminum hydride,~~ in a suitable solvent, ~~preferably hexane,~~ to the corresponding aldehyde of the formula $Y-CHO$ or

c) an alcohol of the formula $Y-CH_2-OH$ according to a) is reacted with a brominating agent, ~~preferably PBr_3 or Ph_3PBr_2~~ to yield the corresponding bromide of the formula $Y-CH_2-Br$ and then worked up and the product is optionally purified,

H) a compound of the formula X^1-R^{IV} , in which X^1 has the above-stated meaning and R^{IV} denotes a functional group, is optionally produced in that

a) 1,4-cyclohexanedione monoethylene ketal, 4-oxocyclohexan-1-one ethylene ketal or 4-oxocyclohexane carboxylic acid is reacted with magnesium and a brominated or chlorinated, optionally substituted aromatic or heteroaromatic compound in a suitable solvent, ~~preferably dry diethyl ether,~~ at elevated temperature to yield the corresponding coupling product and then the ketal is optionally cleaved by reaction with hydrochloric acid in a suitable solvent, ~~preferably tetrahydrofuran~~ and worked up, optionally followed by purification of the product of the formula $X^{1a}=O$, $X^{1a}-NHR^1$ or $X^{1a}-CO_2H$, in which X^{1a} denotes a group residue of the formula X^{1a} and $R^{1'}$, $R^{2'}$ and Z have the

above-stated meaning and the unoccupied bond line symbolises the bond to the group residue =O, -NHR¹ or -CO₂H,



b) Optionally a ketone of the formula X^{1a}=O is reacted in the presence of a suitable reducing agent, preferably ~~sodium borohydride~~ in a suitable solvent, preferably ~~methanol~~, to yield the corresponding alcohol of the formula X^{1a}-OH, worked up and the product is optionally purified,

c) Optionally a ketone of the formula X^{1a}=O is reacted under nitrogen in a suitable solvent, preferably ~~tetrahydrofuran~~, firstly with ammonium trifluoroacetate and then with glacial acetic acid and sodium triacetoxy borohydride, to yield the corresponding amine of the formula X^{1a}-NH₂, worked up and the product is optionally purified,

d) optionally a carboxylic acid of the formula X^{1a}=CO₂H is activated by reaction with dicyclohexylcarbodiimide or by conversion into the carboxylic acid chloride or a mixed anhydride, reacted with diazomethane in a suitable solvent, preferably ~~ether~~, and then treated with water, worked up and the product of the formula X²-CO-CH₂-OH is optionally purified,

e) optionally the hydroxy group in position 4 of the cyclohexane ring in the group residue X^{1a} is converted into hydrogen, a halogen, an ether, ester, alkyl, or aryl ~~or~~ heteroaryl group, in that

α) in order to introduce an ether group, a compound from one of steps a) -d) is reacted with an aliphatic or cycloaliphatic compound in the presence of a suitable catalyst in a suitable solvent, ~~preferably in the presence of sodium hydride in dimethylformamide or in the presence of potassium hydroxide in dimethyl sulfoxide,~~ or with an alkylating agent in a suitable solvent, ~~preferably with a diazo compound in diethyl ether,~~ or with an aryl ~~or~~ heteroaryl compound in the presence of diethylazo dicarboxylate and triphenylphosphine,

β) in order to introduce a halogen, a compound from one of steps a) -d) is reacted with a halogenating agent in a suitable solvent, preferably with $POCl_3$ in dimethylformamide, with PPh_3/Cl_2 , with PPh_3/Br_2 , with triphenylphosphine/n-chlorosuccinimide or with $HCl/ZnCl_2$,


γ) in order to introduce a hydrogen, a compound from step β) is reacted with hydrogen in the presence of a suitable catalyst, ~~preferably palladium/carbon,~~ in a suitable solvent,

δ) in order to introduce an aliphatic or cycloaliphatic residue or an aryl ~~or~~ heteroaryl group, a compound from

step β) is reacted with an aliphatic or cycloaliphatic boronic acid or a boronic acid ester or an aryl or heteroaryl borodihydroxide compound in the presence of palladium(II) acetate and potassium carbonate in a suitable solvent, ~~preferably a dimethylformamide/water mixture,~~ or

ϵ) in order to introduce an ester group, a compound from one of steps a) -d) is reacted with a carboxylic acid chloride in the presence of a suitable catalyst in a suitable solvent

and then worked up, optionally followed by purification of the compound formed of the formula X^1-R^{IV} , in which X^1 denotes the formula X^1



and R^{IV} , R^2 , and R^3 have the above-stated meaning,

I) a compound of the formula $X-R^{IV}$, in which X has the above-stated meaning and R^{IV} denotes a functional group, is optionally derivatised in that

a) a ketone of the formula $X=O$ is reacted 1) with methoxymethyl triphenylphosphonium chloride under protective

gas in a suitable solvent, preferably in dimethylformamide, in the presence of sodium hydride and then with hydrochloric acid or 2) with $\text{Me}_3\text{S}\cdot\text{BF}_4$ to yield the corresponding aldehyde $\text{X}\cdot\text{CHO}$ extended by one carbon atom,

b) an aldehyde of the formula $\text{X}\cdot\text{CHO}$ according to a) is reacted with a reducing agent, preferably sodium borohydride, in a suitable solvent, ~~preferably an ethanol/water mixture,~~ to yield the corresponding alcohol $\text{X}\cdot\text{CH}_2\cdot\text{OH}$,

c) an alcohol $\text{X}\cdot\text{CH}_2\cdot\text{OH}$ according to b) or of the formula $\text{X}\cdot\text{OH}$ is reacted with a brominating agent, ~~preferably triphenylphosphine dibromide,~~ in a suitable solvent, preferably acetonitrile, to yield the corresponding bromide of the formula $\text{XCH}_2\cdot\text{Br}$ or $\text{X}\cdot\text{Br}$,

d) a bromide of the formula $\text{X}\cdot\text{CH}_2\cdot\text{Br}$ according to c) is reacted with a phosphifile of the formula PR^{V}_3 , in which R^{V} denotes an organic group residue, ~~preferably a phenyl residue,~~ in a suitable solvent, preferably toluene, ether, tetrahydrofuran or acetone, with cooling and under protective gas to yield the corresponding phosphonium salt $\text{R}^{\text{V}}_3\text{P}^+\cdot\text{CHX}$ or

e) a bromide of the formula $\text{X}\cdot\text{CH}_2\cdot\text{Br}$ according to c) is reacted with a phosphite of the formula $\text{HP}(0)(\text{OR}^{\text{VI}})_2$, in which R^{VI} denotes an organic group residue, at elevated temperature, preferably 200°C , to yield the corresponding phosphonate $(\text{R}^{\text{VI}}\text{O})_2\text{P}(0)\cdot\text{CH}_2\cdot\text{X}$

and then worked up and the product is optionally purified,

J) a compound from step F) or G), in which Y has the above-stated meaning, is reacted with a compound of the formula X^1-R^{IV} from step H) or a compound $X-R^{IV}$ from step I), in which X, X^1 and R^{IV} have the above-stated meaning, in that

a) a carboxylic acid of the formula $Y-COOH$ is reacted with an amine of the formula $X-NH_2$ in the presence of a suitable condensing agent, preferably ~~dicyclohexylcarbodiimide~~, 1-hydroxybenzotriazole and N-methylmorphine, in a suitable solvent, preferably ~~dimethylformamide~~, with formation of an amide bridge,

b) a carboxylic acid of the formula $Y-COOH$ is reacted with an alcohol of the formula $X-OH$ in the presence of a suitable condensing agent in a suitable solvent with formation of an ester bridge, the reaction preferably taking place in the presence of methylimidazole and 1-(mesitylene-2'-sulfonyl)-3-nitro-1,2,4-triazole in tetrahydrofuran or in the presence of ~~dicyclohexylcarbodiimide~~, 1-hydroxybenzotriazole and N-methylmorphine in dimethylformide,

c) a bromide of the formula $Y-CH_2-Br$ is reacted with a compound of the formula $X-CO(CH_2)_p-OH$, in which p has the above-stated meaning, under protective gas in the presence of a suitable catalyst, ~~preferably sodium hydride or potassium tert butylate~~, in a suitable solvent, preferably ~~dimethylformamide~~, with formation of a bridge of the

formula - $\text{CO}(\text{CH}_2)_p\text{-O-CH}_2$,

d) an alcohol of the formula $\text{Y-CH}_2\text{-OH}$ is reacted with a bromide of the formula X-Br under protective gas in the presence of a suitable condensing agent, ~~preferably sodium hydride or potassium tert-butylate,~~ in a suitable solvent, preferably dimethylformamide, with formation of an ether bridge,

e) a bromide of the formula $\text{Y-CH}_2\text{-Br}$ is reacted with an alcohol of the formula X-OH under protective gas in the presence of a suitable condensing agent, ~~preferably sodium hydride or potassium tert-butylate,~~ in a suitable solvent, preferably dimethylformamide, with formation of an ether bridge,

f) an aldehyde of the formula Y-CHO is reacted with an amine of the formula $\text{X-NHR}^{1'}$ in the presence of a suitable reducing agent, ~~preferably sodium cyanoborohydride and sodium triacetoxyborohydride,~~ in a suitable solvent, preferably a mixture of tetrahydrofuran and 1,2-dichloroethane, with formation of an amino bridge,

g) an aldehyde of the formula Y-CHO is reacted with a phosphonium salt $\text{R}''_3\text{P}^+\text{-CHX}^-$, in which R'' has the above-stated meaning, under protective gas in the presence of suitable catalysts in a suitable solvent, preferably in the presence of sodium methanolate in a mixture of hexane, diethyl ether and/or diisopropyl ether or in the presence of sodium hydride, potassium tert-butylate or a lithium

amide in dimethylformamide or dimethyl sulfoxide, with formation of a $-\text{CH}=\text{CH}-$ bridge or

h) an aldehyde of the formula $\text{Y}-\text{CHO}$ is reacted with a phosphonate of the formula $(\text{R}'''\text{O})_2\text{P}(\text{O})-\text{CH}_2-\text{X}$, in which R''' has the above-stated meaning, under protective gas in the presence of suitable catalysts, preferably sodium methanolate, sodium hydroxide, potassium hydroxide, sodium hydride, potassium tert-butyrate or a lithium amide, in a suitable solvent, preferably dimethylformamide, dimethyl sulfoxide, diethyl ether, tetrahydrofuran, with formation of a $-\text{CH}=\text{CH}-$ bridge and

i) optionally the $-\text{CH}=\text{CH}-$ bridge from step g) or h) is hydrogenated by hydrogen, preferably at standard pressure or elevated pressure of up to 100 bar, in the presence of suitable catalysts, preferably transition metals or transition metal compounds, preferably palladium or the salts thereof, rhodium or the complexes thereof, in a suitable solvent, preferably dimethylformamide, methanol or ethanol, at a temperature of between 20 and 100°C with formation of a $-\text{CH}_2-\text{CH}_2-$ bridge and then worked up and the product is optionally purified,

K) optionally the double bond in the 7-membered ring of one of the reaction products from step I) is hydrogenated by hydrogen, preferably at standard pressure or elevated pressure of up to 100 bar, in the presence of suitable catalysts, preferably transition metals or transition metal compounds, preferably

palladium or the salts thereof, rhodium or the complexes thereof, in a suitable solvent, preferably dimethylformamide, methanol or ethanol, at a temperature of between 20 and 100°C and then worked up and the product is optionally purified.

12. (Currently Amended) A pharmaceutical preparation containing at least one ~~substituted benzo[b]azepin-2-one~~ compound of claim 1 ~~or a corresponding tautomer, optionally in the form of the racemate thereof, the pure stereoisomer thereof, in particular enantiomer or diastereomer, or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio or in each case in the form of the acid or base thereof or in the form of the salt thereof, in particular a physiologically acceptable salt, or in each case in the form of the solvate thereof, in particular the hydrate, according to one of claims 1-10,~~ and optionally physiologically acceptable auxiliary substances.

13. (Currently Amended) A method of treating pain in a patient in need thereof comprising administering to the patient an effective amount of the pharmaceutical preparation according to claim 12 ~~for combatting pain.~~

14. (Currently Amended) The method A pharmaceutical preparation according to claim 13 ~~for combatting~~ where the pain is selected from chronic pain or neuropathic pain.

15. (Cancelled).

16. (Currently Amended) A method of treating neurodegenerative diseases, selected from Alzheimer's disease, Parkinson's disease and Huntington's chorea in a patient in need thereof comprising administering to the patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 for the treatment or prevention of neurodegenerative diseases, preferably of Alzheimer's disease, Parkinson's disease or Huntington's chorea.

17. (Currently Amended) A method of treating stroke comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 for the treatment or prevention of stroke.

18. (Currently Amended) A method of treating cerebral ischaemia comprising administering to the patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 for the treatment or prevention of cerebral ischaemia.

19. (Currently Amended) A method of treating cerebral infarct comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 A pharmaceutical preparation according to claim 12 for the treatment or prevention of cerebral infarct.

20. (Currently Amended) A method of treating cerebral oedema comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to

claim 12 A pharmaceutical preparation according to claim 12 for the treatment or prevention of cerebral oedema.

21. (Currently Amended) A method of treating central nervous system, preferably hypoxia or anoxia comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of insufficiency states of the central nervous system, preferably hypoxia or anoxia.~~

22. (Currently Amended) A method of treating epilepsy comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of epilepsy.~~

23. (Currently Amended) A method of treating schizophrenia comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of schizophrenia.~~

24. (Currently Amended) A method of treating psychoses brought about by elevated amino acid levels comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of psychoses brought about by elevated amino acid levels.~~

25. (Currently Amended) A method of treating AIDS dementia comprising administering to a patient in need thereof an

effective amount of a A pharmaceutical preparation according to
claim 12 for the treatment or prevention of AIDS dementia.

26. (Currently Amended) A method of treating Tourette's
syndrome comprising administering to a patient in need thereof
an effective amount of a A pharmaceutical preparation according
to claim 12 for the treatment or prevention of Tourette's
syndrome.

27. (Currently Amended) A method of treating encephalomyelitis
comprising administering to a patient in need thereof an
effective amount of a A pharmaceutical preparation according to
claim 12 A pharmaceutical preparation according to claim 12 for
the treatment or prevention of encephalomyelitis.

28. (Currently Amended) A method of treating perinatal asphyxia
comprising administering to a patient in need thereof an
effective amount of a A pharmaceutical preparation according to
claim 12 A pharmaceutical preparation according to claim 12 for
the treatment or prevention of perinatal asphyxia.

29. (Currently Amended) A method of treating tinnitus
comprising administering to a patient in need thereof an
effective amount of a A pharmaceutical preparation according to
claim 12 for the treatment or prevention of tinnitus.

30. (Currently Amended) A method of treating migraine
comprising administering to a patient in need thereof an
effective amount of a A pharmaceutical preparation according to
claim 12 for the treatment or prevention of migraine.

31. (Currently Amended) A method of treating inflammatory and/or allergic reactions comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of inflammatory and/or allergic reactions.~~

32. (Currently Amended) A method of treating depression comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of depression.~~

33. (Currently Amended) A method of treating mental health conditions comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of mental health conditions.~~

34. (Currently Amended) A method of treating urinary incontinence comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of urinary incontinence.~~

35. (Currently Amended) A method of treating pruritus comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of pruritus.~~

36. (Currently Amended) A method of treating diarrhea comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for the treatment or prevention of diarrhoea.~~

37. (Currently Amended) A method of treating anxiolysis comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for anxiolysis.~~

38. (Currently Amended) A method of treating anaesthesia comprising administering to a patient in need thereof an effective amount of a A pharmaceutical preparation according to claim 12 ~~for anaesthesia.~~

39. (Currently Amended) A method of treating a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of formula I of claim 1 to treat ~~Use of at least one substituted benzo[b]azepin-2-one compound or a tautomer thereof, optionally in the form of the racemate thereof, the pure stereoisomer thereof, in particular enantiomer or diastereomer, or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio or in each case in the form of the acid or base thereof or in the form of the salt thereof, in particular a physiologically acceptable salt, or in each case in the form of the solvate thereof, in particular the hydrate, according to one of claims 1-10 for the production of a pharmaceutical preparation for the combatting of pain, preferably of chronic or neuropathic pain.~~

40. (Currently Amended) ~~Use of at least one substituted benzo[b]azepin 2 one compound or a tautomer thereof, optionally in the form of the racemate thereof, the pure stereoisomer thereof, in particular enantiomer or diastereomer, or in the form of mixtures of the stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio or in each case in the form of the acid or base thereof or in the form of the salt thereof, in particular a physiologically acceptable salt, or in each case in the form of the solvate thereof, in particular the hydrate, according to one of claims 1-10 for the production of a pharmaceutical preparation~~ A method of treating a subject in need thereof comprising administering to the subject a therapeutically effective amount of the compound of formula I of claim 1 to treat ~~for the treatment or prevention of neurodegenerative diseases, including preferably Alzheimer's disease, Parkinson's disease~~ or and ~~Huntington's chorea, for the treatment or prevention of stroke, cerebral ischaemia, cerebral infarct, cerebral oedema, insufficiency states of the central nervous system, including preferably hypoxia or anoxia, epilepsy, schizophrenia, psychoses brought about by elevated amino acid levels, AIDS dementia, encephalomyelitis, Tourette's syndrome, perinatal asphyxia, tinnitus, migraine, inflammatory and/or allergic reactions, depression mental health conditions, urinary incontinence, pruritus, or diarrhoea, or for anxiolysis or and~~ anaesthesia.

41. (New) A compound of claim 1 wherein the compound is in the form of enantiomers or diastereomers, mixtures of the

USSN 10/824,244

Atty Docket 785-011767

Response to Office Action of December 14, 2004

Page 34

enantiomers or diastereomers, physiologically acceptable salts,
or in the form of hydrates.